Rat's Rant: What's hot, what's not and... the Bali anniversary
Archived
Oct 2, 2019
|
10 min
Actinogen closed up 466% to finish at 5.1c on $15.8 million stock traded. The company announced results from the XanaHES (Xanamem in Healthy Elderly Subjects) trial. The results demonstrate a significant improvement in cognition in trial participants dosed with Xanamem 20mg daily for 12 weeks, compared to placebo.
